- Record: found
- Abstract: not found
- Article: not found
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
J.C. Osorio ,
A. Ni ,
J.E. Chaft ,
R. Pollina ,
M.K. Kasler ,
D. Stephens ,
C. Rodriguez ,
L. Cambridge ,
H. Rizvi ,
J.D. Wolchok ,
T. Merghoub ,
C.M. Rudin ,
S. Fish ,
M.D. Hellmann
March 2017
March 2017
Read this article at
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Programmed cell death protein-1 (PD-1) blockade therapies have demonstrated durable
responses and prolonged survival in a variety of malignancies. Treatment is generally
well tolerated although immune-related adverse events (irAEs) can occur. Autoimmune
thyroid dysfunction is among the most common irAE, but an assessment of the clinical,
mechanistic, and immunologic features has not been previously described.